Industry > Technology Transfer > Accuri Cytometers

Accuri Cytometers

accuri logo
Founded: 2005
Founders: Collin Rich (MSE PhD EE '97 '00), Jennifer Baird
Product/Service: Low-cost, high-performance cell analysis systems
Location: Ann Arbor, MI
St. Ives, Cambridgeshire, England
Acquired By: BD Mar 18, 2011

videoAccuri Cytometers, Inc. was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument.
[Accuri Cytometers Website, About Us]

In the News

Nov 11, 2012

UM Startups Amaze As Tech Tour Continues

"Accuri Cytometers, was born out of a professor's idea to use microfluidics to detect bacteria in machine tool fluid, which can make workers sick. The Detroit Three and the United Auto Workers were behind the original idea. Eventually, though, the business types who were leading the commercialization effort figured out that the idea wouldn't work as an inexpensive way to detect nasty bugs on factory floors — but it would work as a desktop cell analyzer, "a low cost way of analyzing bugs period, so instead of a quarter million dollar machine, we can make one for $25,000," Nisbet said. Accuri Cytometers was born, and detailed cell analysis went from room-size to desk size, and the cost fell by 90 percent."

© CBS Detroit

Mar 30, 2011

Accuri Exit Showers Michigan With A Lot Of Love

The more you look at Becton, Dickinson & Co.’s (NYSE:BDX) recently completed acquisition of Accuri Cytometers in Ann Arbor, MI, the more there is to like. Even savor.

BD did not disclose financial terms, which is a little annoying since the medical device and equipment maker, based in Franklin Lakes, NJ, had no problem telling the world it paid $275 million for HandyLabs, another Ann Arbor startup, in 2009.

But thanks to a helpful source with knowledge of the situation, I learned BD paid $205 million for Accuri, a University of Michigan spinoff that makes sophisticated machines that count cells. That means BD has dropped nearly half a billion dollars on two Michigan startups in less than three years.

Expand this Article   Hide

© Xconomy Detroit. Thomas Lee:

bd logoMar 18, 2011

BD Completes Acquisition of Accuri Cytometers, Inc.

Franklin Lakes, NJ (March 18, 2011)—BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the completion of its acquisition of Accuri Cytometers, Inc., an Ann Arbor, Michigan-based company that develops and manufactures personal flow cytometers for researchers. 

The acquisition expands BD’s presence into the emerging affordable personal flow cytometer space, and helps expand the use of flow cytometry technology by researchers in regions of the world where ease of use and affordability are critical.

“The acquisition of Accuri Cytometers complements and broadens BD’s offerings for life scientists by making flow cytometry more accessible to a wider audience of scientists and clinicians,” said William Rhodes, President, BD Biosciences. “This includes researchers in scientific disciplines that have not traditionally used flow cytometry, such as environmental sciences, microbiology and marine biology.”

The financial impact of the acquisition on fiscal year 2011 earnings has been incorporated into the guidance BD provided during its earnings call on February 8, 2011.

© Becton, Dickinson and Company Press Release. Colleen T. White, Corporate Communications: (201) 847-5369, and Zachary A. Nagle, Investor Relations: (201) 847-5453,

ann logoFeb 7, 2011

Promising medical devices firm Accuri Cytometers sold to same company that bought HandyLab

New Jersey-based giant Becton, Dickinson and Co. said this afternoon that it had reached a deal to acquire medical device firm Accuri Cytometers, one of the Ann Arbor region's most promising tech companies.

Terms of the deal were not disclosed, but the transaction is expected to be finished in BD's third fiscal quarter of 2011, which lines up with the spring.

Expand this Article   Hide

@ Nathan Bomey: (734) 623-2587,